Gemma Iserte
Overview
Explore the profile of Gemma Iserte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Diaz-Gonzalez A, Sapena V, Boix L, Brunet M, Torres F, Llarch N, et al.
Liver Int
. 2020 Oct;
40(10):2476-2488.
PMID: 33021346
Background & Aims: Sorafenib and lenvatinib are the first-line treatments approved in hepatocellular carcinoma (HCC), but information is lacking about the relationships between their pharmacokinetics, patients pharmacogenetic profiles, adverse events...
12.
Diaz-Gonzalez A, Belmonte E, Sapena V, Sanduzzi-Zamparelli M, Darnell A, Diaz A, et al.
J Clin Gastroenterol
. 2020 Jun;
55(3):263-270.
PMID: 32530871
Goals: To describe the occurrence of malabsorption (MA) in hepatocellular carcinoma (HCC) patients under sorafenib, the potential relationship with pancreatic insufficiency (PI), and the role of pancreatic enzymes supplementation. Background:...
13.
Diaz-Gonzalez A, Sanduzzi-Zamparelli M, Sapena V, Torres F, Llarch N, Iserte G, et al.
Aliment Pharmacol Ther
. 2019 Jan;
49(5):482-491.
PMID: 30695819
Background: The positive results of the REFLECT trial in terms of survival (sorafenib vs lenvatinib) offer a new first-line option for hepatocellular carcinoma. Additionally, the expected results of immunotherapy could...